Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Ashcroft

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Trials|March 9, 2018
The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trialAlina Striha, A John Ashcroft, Anna Hockaday, et al.
Oncogene|February 20, 2003
Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanismJames A L Fenton, Guy Pratt, Andy C Rawstron, et al.
Journal of Bone Oncology|June 22, 2019
Unplanned admissions for patients with myeloma in the UK: Low frequency but high costsSpyros Kolovos, Guido Nador, Bhuvan Kishore, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 2, 2016
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) TrialChristopher Parrish, Curly T C M Morris, Cathy D Williams, et al.
The Lancet. Oncology|June 21, 2014
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trialGordon Cook, Cathy Williams, Julia M Brown, et al.
The Lancet. Haematology|September 9, 2024
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trialGordon Cook, A John Ashcroft, Ethan Senior, et al.
Lancet (London, England)|December 7, 2010
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
The Lancet. Haematology|July 5, 2016
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trialGordon Cook, A John Ashcroft, David A Cairns, et al.
British Journal of Haematology|May 21, 2024
Inflammatory profile of lower risk myelodysplastic syndromesJoanne Topping, Adele Taylor, Fatima Nadat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2019
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple MyelomaSam H Ahmedzai, John A Snowden, Andrew John Ashcroft, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Trials|March 9, 2018
The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trialAlina Striha, A John Ashcroft, Anna Hockaday, et al.
Oncogene|February 20, 2003
Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanismJames A L Fenton, Guy Pratt, Andy C Rawstron, et al.
Journal of Bone Oncology|June 22, 2019
Unplanned admissions for patients with myeloma in the UK: Low frequency but high costsSpyros Kolovos, Guido Nador, Bhuvan Kishore, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 2, 2016
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) TrialChristopher Parrish, Curly T C M Morris, Cathy D Williams, et al.
The Lancet. Oncology|June 21, 2014
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trialGordon Cook, Cathy Williams, Julia M Brown, et al.
The Lancet. Haematology|September 9, 2024
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trialGordon Cook, A John Ashcroft, Ethan Senior, et al.
Lancet (London, England)|December 7, 2010
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
The Lancet. Haematology|July 5, 2016
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trialGordon Cook, A John Ashcroft, David A Cairns, et al.
British Journal of Haematology|May 21, 2024
Inflammatory profile of lower risk myelodysplastic syndromesJoanne Topping, Adele Taylor, Fatima Nadat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2019
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple MyelomaSam H Ahmedzai, John A Snowden, Andrew John Ashcroft, et al.
Pageof 4